M. Stojanovic

1.4k total citations · 1 hit paper
18 papers, 1.0k citations indexed

About

M. Stojanovic is a scholar working on Pathology and Forensic Medicine, Cellular and Molecular Neuroscience and Neurology. According to data from OpenAlex, M. Stojanovic has authored 18 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 5 papers in Cellular and Molecular Neuroscience and 5 papers in Neurology. Recurrent topics in M. Stojanovic's work include Multiple Sclerosis Research Studies (9 papers), Peripheral Neuropathies and Disorders (5 papers) and Hereditary Neurological Disorders (4 papers). M. Stojanovic is often cited by papers focused on Multiple Sclerosis Research Studies (9 papers), Peripheral Neuropathies and Disorders (5 papers) and Hereditary Neurological Disorders (4 papers). M. Stojanovic collaborates with scholars based in Serbia, United Kingdom and Czechia. M. Stojanovic's co-authors include Stephen Lake, Eva Havrdová, Alasdair Coles, Krzysztof Selmaj, Vesna Brinar, Douglas L. Arnold, David Margolin, Gavin Giovannoni, Howard L. Weiner and Jeffrey Cohen and has published in prestigious journals such as The Lancet, Neurology and Journal of the Neurological Sciences.

In The Last Decade

M. Stojanovic

18 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

2012 883 citations Jeffrey Cohen, Alasdair Coles et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Stojanovic Serbia	8	815	361	271	249	241	18	1.0k
Amy Pace United States	8	1.0k 1.2×	555 1.5×	300 1.1×	282 1.1×	252 1.0×	15	1.2k
Pierangelo Barbero Italy	15	623 0.8×	408 1.1×	259 1.0×	289 1.2×	134 0.6×	34	951
Pedro Oyuela United States	7	938 1.2×	362 1.0×	368 1.4×	286 1.1×	326 1.4×	16	1.2k
Marianna Manfrini Switzerland	7	737 0.9×	325 0.9×	221 0.8×	167 0.7×	205 0.9×	21	868
Paul O’Connor Canada	11	926 1.1×	329 0.9×	284 1.0×	294 1.2×	220 0.9×	22	1.1k
Tamara Miller United States	6	799 1.0×	319 0.9×	288 1.1×	247 1.0×	244 1.0×	23	958
Aaron Miller United Kingdom	3	910 1.1×	503 1.4×	214 0.8×	300 1.2×	184 0.8×	5	1.1k
Karthinathan Thangavelu United States	14	585 0.7×	226 0.6×	240 0.9×	206 0.8×	161 0.7×	58	779
Bella Ertik United States	5	756 0.9×	286 0.8×	272 1.0×	236 0.9×	248 1.0×	7	930
T. Pickersgill United Kingdom	8	582 0.7×	253 0.7×	141 0.5×	192 0.8×	193 0.8×	12	730

Countries citing papers authored by M. Stojanovic

Since Specialization

Citations

This map shows the geographic impact of M. Stojanovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Stojanovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Stojanovic more than expected).

Fields of papers citing papers by M. Stojanovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Stojanovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Stojanovic. The network helps show where M. Stojanovic may publish in the future.

Co-authorship network of co-authors of M. Stojanovic

This figure shows the co-authorship network connecting the top 25 collaborators of M. Stojanovic. A scholar is included among the top collaborators of M. Stojanovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Stojanovic. M. Stojanovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Stojanov, Aleksandar, Ivana Berisavac, Ivo Božović, et al.. (2020). Incidence and mortality rates of Guillain‐Barré syndrome in Serbia. Journal of the Peripheral Nervous System. 25(4). 350–355. 10 indexed citations

Berisavac, Ivana, Ivo Božović, Aleksandra Kačar, et al.. (2020). Disability and quality of life in Guillain-Barré syndrome – Longitudinal study. Journal of Clinical Neuroscience. 78. 185–188. 7 indexed citations

Bjelica, Bogdan, Ivana Basta, Ivo Božović, et al.. (2018). Employment status of patients with chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System. 23(3). 178–182. 4 indexed citations

Kačar, Aleksandra, Bogdan Bjelica, Ivo Božović, et al.. (2018). Neuromuscular disease‐specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System. 23(1). 11–16. 17 indexed citations

Božović, Ivo, Aleksandra Kačar, Stojan Perić, et al.. (2017). Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neurology. 264(12). 2481–2486. 26 indexed citations

Stojanovic, M., Goran Stanojević, Milan Radojković, et al.. (2016). RELATIONSHIP BETWEEN SUBJECTIVE DISCOMFORTS AND EVALUTION OF DIAGNOSTIC PROCEDURES BASED ON THE STAGES OF CHRONICAL ARTERY INSUFFICIENCY OF LOWER EXTREMITIES. Acta Medica Medianae. 55(3). 44–56. 1 indexed citations

Arnold, Douglas L., Elizabeth Fisher, Vesna Brinar, et al.. (2016). Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS. Neurology. 87(14). 1464–1472. 27 indexed citations

Lycke, Jan, Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Adverse event profile of alemtuzumab over time in treatment-naïve patients with early, active relapsing–/INS;remitting multiple sclerosis (RRMS; CARE-MS I study). Journal of the Neurological Sciences. 333. e374–e375. 6 indexed citations

Balcer, Laura J., Douglas L. Arnold, Jeffrey Cohen, et al.. (2013). Alemtuzumab improves visual outcomes in treatment-naïve patients with relapsing–/INS;remitting multiple sclerosis (RRMS): Analysis from the phase 3 CARE-MS I study. Journal of the Neurological Sciences. 333. e375–e375. 5 indexed citations

10.

Margolin, David, Gary D. Smith, Douglas L. Arnold, et al.. (2013). Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy. Journal of the Neurological Sciences. 333. e375–e376. 7 indexed citations

11.

Cohen, Jeffrey, Alasdair Coles, Douglas L. Arnold, et al.. (2012). Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet. 380(9856). 1819–1828. 883 indexed citations breakdown →

12.

Fox, Edward, Douglas L. Arnold, Vesna Brinar, et al.. (2012). Relapse Outcomes with Alemtuzumab vs. Rebif(R) in Treatment-Naive Relapsing-Remitting Multiple Sclerosis (CARE-MS I): Secondary and Tertiary Endpoints (PD5.004). Neurology. 78(Meeting Abstracts 1). PD5.004–PD5.004. 3 indexed citations

13.

Havrdová, Eva, Douglas L. Arnold, Alasdair Coles, et al.. (2012). Infections in Phase 3 Study: Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis I (CARE-MS I) (S41.007). Neurology. 78(Meeting Abstracts 1). S41.007–S41.007. 2 indexed citations

14.

Živanović, Dragoljub, et al.. (2012). SUPRACONDYLAR FRACTURE OF THE HUMERUS IN CHILDREN. Acta Medica Medianae. 5–12. 4 indexed citations

15.

Arnold, Douglas L., Vesna Brinar, J. A. Cohen, et al.. (2012). Effect of Alemtuzumab vs. Rebif(R) on Brain MRI Measurements: Results of CARE-MS I, a Phase 3 Study (S11.006). Neurology. 78(Meeting Abstracts 1). S11.006–S11.006. 5 indexed citations

16.

Coles, Alasdair, Vesna Brinar, Douglas L. Arnold, et al.. (2012). Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis I (CARE-MS I): A Phase 3 Study in Relapsing-Remitting Treatment-Naive Patients (S01.006). Neurology. 78(Meeting Abstracts 1). S01.006–S01.006. 5 indexed citations

17.

Selmaj, Krzysztof, Douglas L. Arnold, Vesna Brinar, et al.. (2012). Incidence of Autoimmunity in a Phase 3 Trial: Comparison of Alemtuzumab and Rebif(R) in Multiple Sclerosis I (CARE-MS I) (S41.006). Neurology. 78(Meeting Abstracts 1). S41.006–S41.006. 3 indexed citations

18.

Kostić, Vladimir, et al.. (1989). Degenerative neurological disorders associated with deficiency of glutamate dehydrogenase. Journal of Neurology. 236(2). 111–114. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact